Company achieved significant commercial progress in 2024, finishing with total U.S. net product sales revenue of approximately $319 million (unaudited) Company reaffirms peak U.S. net IBSRELA sales re ...
Akebia has since engaged with the FDA on potentially expanding vadadustat treatment to this patient population and has received feedback on a protocol submitted for a Phase 3 cardiovascular outcome ...
After decades of studies and reports on the continuing degradation of Oklahoma's waterways, organizations like Save The Illinois River and Spring Creek Coalition wonder why the data are not being ...
Most top nutrition experts agree: Cutting back on ultra-processed foods is a good way to improve your health. But not all ultra-processed foods are created equal. Some are better for you than others.
Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that data from ...
This round of financing will support Alebund in advancing the development and commercial activities of its pipelines in renal disease and to accelerate the development of multiple clinical-stage ...
A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. | The Fierce Biotech Fundraising Tracker records ...
such as binders, fillers, and additives. Look for products with minimal additional ingredients and avoid those with potentially harmful additives. Phosphorus supplements are available in different ...